Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); ISTA, PEARL Interims Expected Mid-to-late March
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $13.00.
Analyst, Ritu Baral, said, "Reiterating rating and price target on good chance of blisibimod Phase 2/3 lupus success and positive Phase 3 varespladib acute coronary syndrome (ACS) data in 2012. Blisibimod is ANTH’s Phase 2/3 BAFF peptibody for lupus, which we think will yield positive data from the ongoing PEARL-SC trial mid 2012. We also think sPLA2 inhibitor varespladib will show meaningful benefit in post-ACS CV risk in H2/12 from the ongoing VISTA-16 trial."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $7.37 yesterday.
Analyst, Ritu Baral, said, "Reiterating rating and price target on good chance of blisibimod Phase 2/3 lupus success and positive Phase 3 varespladib acute coronary syndrome (ACS) data in 2012. Blisibimod is ANTH’s Phase 2/3 BAFF peptibody for lupus, which we think will yield positive data from the ongoing PEARL-SC trial mid 2012. We also think sPLA2 inhibitor varespladib will show meaningful benefit in post-ACS CV risk in H2/12 from the ongoing VISTA-16 trial."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $7.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Rubrik Inc (RBRK) PT Raised to $120 at Cantor Fitzgerald Into Q2 Earnings
- Raymond James Starts Southern California Bancorp (BCAL) at Outperform
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
